<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Yonsei Med J</journal-id>
      <journal-id journal-id-type="publisher-id">YMJ</journal-id>
      <journal-title-group>
        <journal-title>Yonsei Medical Journal</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0513-5796</issn>
      <issn pub-type="epub">1976-2437</issn>
      <publisher>
        <publisher-name>Yonsei University College of Medicine</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">18306484</article-id>
      <article-id pub-id-type="pmc">2615276</article-id>
      <article-id pub-id-type="doi">10.3349/ymj.2008.49.1.159</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Successful Etanercept Therapy for Refractory Sacroiliitis in a Patient with Ankylosing Spondylitis and Mixed Connective Tissue Disease</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>Jee Young</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chang</surname>
            <given-names>Hyun Kyu</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Kim</surname>
            <given-names>Seong-Kyu</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Department of Diagnostic Radiology, College of Medicine, Dankook University, Cheonan, Korea.</aff>
      <aff id="A2"><label>2</label>Chang Hyn Kyu Rheumatism Clinic, Cheonan, Korea.</aff>
      <aff id="A3"><label>3</label>Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea.</aff>
      <author-notes>
        <corresp>
Reprint address: requests to Dr. Seong-Kyu Kim, Department of Internal Medicine, Catholic University of Daegu School of Medicine, 3056-6 Daemyung4-dong, Nam-gu, Daegu 705-718, Korea. Tel: 82-53-650-3038, Fax: 82-53-629-8248, <email>kimsk714@cu.ac.kr</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>29</day>
        <month>2</month>
        <year>2008</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>20</day>
        <month>2</month>
        <year>2008</year>
      </pub-date>
      <volume>49</volume>
      <issue>1</issue>
      <fpage>159</fpage>
      <lpage>162</lpage>
      <history>
        <date date-type="received">
          <day>11</day>
          <month>9</month>
          <year>2006</year>
        </date>
        <date date-type="accepted">
          <day>09</day>
          <month>10</month>
          <year>2006</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2008 The Yonsei University College of Medicine</copyright-statement>
        <copyright-year>2008</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">http://creativecommons.org/licenses/by-nc/3.0</ext-link>) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>The concurrence of ankylosing spondylitis (AS) in a patient with mixed connective tissue disease (MCTD) is rarely described in the literature. Significant and sustained efficacy with tumor necrosis factor (TNF)-&#x3B1; blockers has been demonstrated in AS patients. However, evidence to date has revealed associated side effects, including antinuclear antibody induction and development of a lupus-like syndrome. Several authors have reported lupus-like manifestations in MCTD patients treated with TNF-&#x3B1; blockers used to control peripheral polyarthritis. In our case report, we demonstrate a good response to etanercept therapy for refractory sacroiliitis in a patient with coexisting AS and MCTD, without development of a lupus-like syndrome. This demonstrates that etanercept therapy may be an appropriate therapeutic agent for sacroiliitis in MCTD patients, as it is in AS alone.</p>
      </abstract>
      <kwd-group>
        <kwd>Ankylosing spondylitis</kwd>
        <kwd>mixed connective tissue disease</kwd>
        <kwd>etanercept</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Mixed connective tissue disease (MCTD) was first described as a distinct disease entity characterized by high titers of anti-U1-ribonecleic protein (RNP) antibodies.<xref ref-type="bibr" rid="B1">1</xref> With certain sets of diagnostic criteria, clinical manifestations of MCTD are similar, or intermingled, with those of other connective tissue diseases, including systemic lupus erythematosus (SLE), polymyositis, and systemic sclerosis.<xref ref-type="bibr" rid="B2">2</xref> However, a concurrence of ankylosing spondylitis (AS) and MCTD has rarely been reported, in spite of their being clinically distinct entities.<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref></p>
      <p>Most MCTD patients with arthritis respond well to treatment with nonsteroidal anti-inflammatory drugs (NSAIDs), hydroxychloroquine, and/or an oral, low-dose steroid. TNF-&#x3B1; blockers, including etanercept or infliximab, are also effective in controlling polyarthritis in MCTD patients,<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref> although side effects of lupus-like manifestations have been described. Treatment with TNF-&#x3B1; blockers in AS has also shown significant clinical efficacy.<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref> We present a patient with AS sacroiliitis and MCTD who showed good response to etanercept without development of a lupus-like syndrome.</p>
    </sec>
    <sec sec-type="cases">
      <title>CASE REPORT</title>
      <p>A 45-year-old female presented with Raynaud's phenomenon, photosensitivity, edematous fingers and hands, and polyarthritis in April 2004. She also complained of a three-year history of low back pain with morning stiffness that improved with exercise and worsened with resting.</p>
      <p>Physical examination revealed symmetrical edematous fingers and hands bilaterally, with pain and limited motion of the right shoulder. Chest wall expansion was estimated at 3cm, and lumbar spine motion was approximately 2cm. Sacroiliac joint tenderness on palpation was noted.</p>
      <p>Immunological analyses revealed positive anti-nuclear antibody (ANA) with specked pattern (titer of 1:1280, normal &lt; 1:40), and positive anti-RNP antibody (titer of 965, normal &lt; 150). Antibodies for double-stranded DNA, Sm, SS-A/Ro, SS-B/La, centromere, Scl-70, and Jo-1 were negative. Anti-neutrophil cytoplasmic antibody, anti-cardiolipin antibody, cryoglobulin, VDRL, and rheumatoid factor were not detected. HLA-B27 antigen was positive.</p>
      <p>On radiographic examination of the pelvis, grade 2 bilateral sacroiliitis was diagnosed according to the modified New York classification. However, typical cervical and lumbar spine syndesmophytes were not identified. Magnetic resonance imaging (MRI) revealed active bilateral sacroiliitis (<xref ref-type="fig" rid="F1">Fig. 1A</xref>). Echocardiography identified pulmonary arterial hypertension, with a pulmonary arterial pressure of less than 25mmHg. Positive Raynaud's phenomenon using Raynaud's scan and infrared thermographic imaging was also confirmed.</p>
      <p>AS was diagnosed according to the modified New York criteria,<xref ref-type="bibr" rid="B9">9</xref> and MCTD was diagnosed by the Alarcon-Segovia's criteria.<xref ref-type="bibr" rid="B10">10</xref> Polyarthritis symptoms, except low back pain and Raynaud's phenomenon, improved with combination therapy of hydroxychloroquine, NSAIDs, and low-dose corticosteroids, and right shoulder pain resolved following intraarticular steroid injection.</p>
      <p>Four months later, the patient was readmitted for buttock and sacroiliac joint pain. Clinically significant pain reduction was not achieved using computed tomography-guided intraarticular injection of 40mg of triamcinolone acetate. A 25-mg dose of soluble TNF-&#x3B1; receptor, etanercept, was started twice weekly for four weeks in combination with NSAIDs and corticosteroids. The patient had pain reduction and no occurrence of lupus-like symptoms.</p>
      <p>MRI examination of the sacroiliac joint was assessed at 18 months. A significant decrease in inflammation was identified, without development of new lesions (<xref ref-type="fig" rid="F1">Fig. 1B</xref>); this suggested the effectiveness of etanercept for sacroiliitis in patients with MCTD. Unfortunately, mild pulmonary arterial hypertension of approximately 37mmHg developed. The patient's treatment continued with NSAIDs, hydroxychloroquine, low-dose corticosteroid, and a calcium channel blocker. She reported a tolerable level of low back pain around the sacroiliac joints.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>MCTD patients share a number of clinical features, including Raynaud's phenomenon, puffy hands, arthralgia, mild arthritis, myositis, and a high level of antibodies to U1-RNP. Several diagnostic criteria for MCTD have been described in patients with overlapping manifestations of SLE, RA, systemic sclerosis, and polymyositis.<xref ref-type="bibr" rid="B2">2</xref> In addition, evidence of coexistence of spondyloarthropathy and connective tissue diseases, especially Sj&#xF6;gren's syndrome or sicca syndrome, has previously been described.<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref> Our case was a rare concurrence of AS and MCTD.</p>
      <p>Inflammatory manifestations in MCTD (including arthritis, serositis, fever, and skin rash) respond relatively well to NSAIDs or corticosteroids, whereas patients with major organ involvement tend to have persistent symptoms and often fail to have significant improvement of Raynaud's phenomenon, interstitial lung disease, scleroderma-like skin thickening, or pulmonary hypertension.<xref ref-type="bibr" rid="B13">13</xref> Arthritis in MCTD patients is responsive to NSAIDs, hydroxychloroquine, and/ or low-dose corticosteroids. Our patient with mild and nonerosive polyarthritis had significant improvement following combination therapy. Patients with more destructive and erosive arthritis may require more aggressive therapies, including methotrexate, leflunomide, or azathioprine.<xref ref-type="bibr" rid="B13">13</xref></p>
      <p>Data on TNF-&#x3B1; blockers efficacy and safety have been recognized for multiple diseases with inflammatory peripheral arthritis or axial arthritis /spondylitis, including RA and AS.<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B14">14</xref> Treatment has been associated with diverse autoimmune toxicities, including anti-double-stranded DNA antibody induction and development of systemic, lupus-like syndromes or a cutaneous, lupus-like rash, although the etiology of aberrant immune responses it is not clearly understood.<xref ref-type="bibr" rid="B15">15</xref> We proposed that our patient with MCTD and bilateral refractory sacroiliitis unresponsive to NSAIDs and intraarticular steroid injections may do well with TNF-&#x3B1; blocker therapy, as do AS patients. However, two reports previously described development of a lupus-like syndrome in MCTD patients.<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref> In this case we used etanercept with good result, and without occurrence of clinical features consistent with lupus-like syndrome, such as myalgia, fever, arthralgia, or skin rash.</p>
      <p>As our patient had MRI scanning at 18 months, it is impossible to predict time of sacroiliac lesion improvement. However, a German study group found significant regression on MRI of active sacroiliitis following 6 weeks of treatment.<xref ref-type="bibr" rid="B16">16</xref> For more accurate assessment, periodic MRI examination, development of an MRI scoring system, and standardized dosing and duration of etanercept in a large population study would be required.</p>
      <p>We report safe and effective use of etanercept for sacroiliitis in a patient with MCTD with evidence of symptomatic and radiological improvement. The results of these few case reports show that there may be efficacy in the use of anti-TNF therapy in MCTD-related polyarthritis. If used, patients should be warned of the risk of development of a lupus-like syndrome.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sharp</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Irvin</surname>
              <given-names>WS</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Gould</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Holman</surname>
              <given-names>HR</given-names>
            </name>
          </person-group>
          <article-title>Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA)</article-title>
          <source>Am J Med</source>
          <year>1972</year>
          <volume>52</volume>
          <fpage>148</fpage>
          <lpage>159</lpage>
          <pub-id pub-id-type="pmid">4621694</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alarc&#xF3;n-Segovia</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Cardiel</surname>
              <given-names>MH</given-names>
            </name>
          </person-group>
          <article-title>Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients</article-title>
          <source>J Rheumatol</source>
          <year>1989</year>
          <volume>16</volume>
          <fpage>328</fpage>
          <lpage>334</lpage>
          <pub-id pub-id-type="pmid">2724251</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>TH</given-names>
            </name>
            <name>
              <surname>Jun</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Yoo</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>SY</given-names>
            </name>
          </person-group>
          <article-title>Coexistence of ankylosing spondylitis and mixed connective tissue disease in a single patient</article-title>
          <source>Clin Exp Rheumatol</source>
          <year>1999</year>
          <volume>17</volume>
          <fpage>263</fpage>
          <pub-id pub-id-type="pmid">10342061</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brandt</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Maier</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Rudwaleit</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>K&#xFC;hl</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Hiepe</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Sieper</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Co-occurrence of spondyloarthropathy and connective tissue disease: development of Sj&#xF6;gren's syndrome and mixed connective tissue disease (MCTD) in a patient with ankylosing spondylitis</article-title>
          <source>Clin Exp Rheumatol</source>
          <year>2002</year>
          <volume>20</volume>
          <fpage>80</fpage>
          <lpage>84</lpage>
          <pub-id pub-id-type="pmid">11892716</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Richez</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Blanco</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Dumoulin</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Schaeverbeke</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Lupus erythematosus manifestations exacerbated by etanercept therapy in a patient with mixed connective tissue disease</article-title>
          <source>Clin Exp Rheumatol</source>
          <year>2005</year>
          <volume>23</volume>
          <fpage>273</fpage>
          <pub-id pub-id-type="pmid">15895904</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Christopher-Stine</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wigley</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Tumor necrosis factor-alpha antagonists induce lupus-like syndrome in patients with scleroderma overlap/mixed connective tissue disease</article-title>
          <source>J Rheumatol</source>
          <year>2003</year>
          <volume>30</volume>
          <fpage>2725</fpage>
          <lpage>2727</lpage>
          <pub-id pub-id-type="pmid">14719225</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Braun</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Brandt</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Listing</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zink</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Alten</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Golder</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial</article-title>
          <source>Lancet</source>
          <year>2002</year>
          <volume>359</volume>
          <fpage>1187</fpage>
          <lpage>1193</lpage>
          <pub-id pub-id-type="pmid">11955536</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brandt</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Khariouzov</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Listing</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Haibel</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>S&#xF6;rensen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Grassnickel</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis</article-title>
          <source>Arthritis Rheum</source>
          <year>2003</year>
          <volume>48</volume>
          <fpage>1667</fpage>
          <lpage>1675</lpage>
          <pub-id pub-id-type="pmid">12794835</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van der Linden</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Valkenburg</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Cats</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria</article-title>
          <source>Arthritis Rheum</source>
          <year>1984</year>
          <volume>27</volume>
          <fpage>361</fpage>
          <lpage>368</lpage>
          <pub-id pub-id-type="pmid">6231933</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Alarcon-Segovia</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Villareal</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Kasukawa</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sharp</surname>
              <given-names>GC</given-names>
            </name>
          </person-group>
          <article-title>Classification and diagnostic criteria for mixed connective tissue disease</article-title>
          <source>Mixed Connective Tissue Disease and Anti-nuclear Antibodies</source>
          <year>1987</year>
          <publisher-loc>Amsterdam</publisher-loc>
          <publisher-name>Elsevier</publisher-name>
          <fpage>33</fpage>
          <lpage>40</lpage>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brandt</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rudwaleit</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Eggens</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Mertz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Distler</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sieper</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Increased frequency of Sj&#xF6;gren's syndrome in patients with spondyloarthropathy</article-title>
          <source>J Rheumatol</source>
          <year>1998</year>
          <volume>25</volume>
          <fpage>718</fpage>
          <lpage>724</lpage>
          <pub-id pub-id-type="pmid">9558175</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scotto di Fazano</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Grilo</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Vergne</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Coyral</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Inaoui</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bonnet</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Is the relationship between spondyloarthropathy and Sj&#xF6;gren's syndrome in women coincidental? A study of 13 cases</article-title>
          <source>Joint Bone Spine</source>
          <year>2002</year>
          <volume>69</volume>
          <fpage>383</fpage>
          <lpage>387</lpage>
          <pub-id pub-id-type="pmid">12184435</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Grossman</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Treatment of mixed connective tissue disease</article-title>
          <source>Rheum Dis Clin North Am</source>
          <year>2005</year>
          <volume>31</volume>
          <fpage>549</fpage>
          <lpage>565</lpage>
          <fpage>viii</fpage>
          <pub-id pub-id-type="pmid">16084325</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scott</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Kingsley</surname>
              <given-names>GH</given-names>
            </name>
          </person-group>
          <article-title>Tumor necrosis factor inhibitors for rheumatoid arthritis</article-title>
          <source>N Engl J Med</source>
          <year>2006</year>
          <volume>355</volume>
          <fpage>704</fpage>
          <lpage>712</lpage>
          <pub-id pub-id-type="pmid">16914706</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shanahan</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>St Clair</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease</article-title>
          <source>Clin Immunol</source>
          <year>2002</year>
          <volume>103</volume>
          <fpage>231</fpage>
          <lpage>242</lpage>
          <pub-id pub-id-type="pmid">12173297</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rudwaleit</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Baraliakos</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Listing</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Brandt</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sieper</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Braun</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept</article-title>
          <source>Ann Rheum Dis</source>
          <year>2005</year>
          <volume>64</volume>
          <fpage>1305</fpage>
          <lpage>1310</lpage>
          <pub-id pub-id-type="pmid">15778243</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" position="float">
      <label>Fig. 1</label>
      <caption>
        <p>(A) Magnetic resonance coronal fat suppressed T2-weighted image (WI) of both sacroiliac joints showing increased signal intensity within the joint spaces and subchondral marrow edema. Also present are subchondral erosions and localized fat deposition in the subchondral marrow spaces. (B) After 18 months, significant improvement of joint spaces with high signal intensity on fat-suppressed T2-WI with subchondral marrow edema identified at the same level.</p>
      </caption>
      <graphic xlink:href="ymj-49-159-g001"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
